Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines

Venus Remedies secures final Rs. 11 crore payment from Cipla for AMR drug

The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019

Wellcome injects £2 million to turbocharge UK regulation of digital mental health tech

Cipla opens India's First dedicated lung health diagnostics center in Delhi

Lupin Foundation bags CRISIL's Highest VO 1A rating for Excellence in Social Responsibility

This distinction is testament to LHWRF's dedication to excellence, transparency, and impact in the realm of social responsibility

Cosmo and Glenmark receives market authorization of Winlevi in Europe

Winlevi is authorized in EU for the treatment of acne vulgaris

HRV Pharma and MetroChem forge CDMO alliance to fast-track NCE-1 API development

Both companies will jointly execute development and scale-up of multiple strategic APIs, including late-stage NCE-1 opportunities

Trump clinches historic deal as Lilly, Novo slash U.S. weight-loss drug prices

Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans

Amgen confident in US biosimilar market’s strength as sales surge 52%

Henkel launches Packaging RecycLab in China

This integrated center combines development, testing, evaluation, and industry-academia-research collaboration